PHAXIAM THERAPEUTICS S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.99 EUR | 0.00% |
|
-1.49% | -56.74% |
| Jul. 03 | Phaxiam: EPIC Bpifrance exceeds 25% of share capital | CF |
| Jun. 28 | Would you like some more inflation? |  |
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-09-24
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.99
EUR
Average target price
5.1
EUR
Spread / Average Target
+156.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.74% | 21.66M | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- Phaxiam Therapeutics Delists from Nasdaq Capital Market
